Literature DB >> 6616244

Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob).

G A Oltmans.   

Abstract

An analysis of the norepinephrine (NE) and dopamine (DA) levels in specific hypothalamic nuclei of the genetically obese mouse (ob/ob) was made. When compared to lean littermate controls ob/ob mice had significantly increased levels of NE in the paraventricular nucleus and lateral hypothalamus and significantly decreased levels of DA in the arcuate-infundibulum. The sites of these neurochemical abnormalities correspond to hypothalamic areas involved in the regulation of feeding and prolactin secretion, both of which are abnormal in the ob/ob mutant.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616244     DOI: 10.1016/0006-8993(83)90865-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Animal models of postinfectious obesity: hypothesis and review.

Authors:  M J Lyons; K Nagashima; J B Zabriskie
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

Review 2.  Neuroendocrine regulation of eating behavior.

Authors:  R Vettor; R Fabris; C Pagano; G Federspil
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

Review 3.  Hypothalamic control of energy and glucose metabolism.

Authors:  Stephanie Sisley; Darleen Sandoval
Journal:  Rev Endocr Metab Disord       Date:  2011-09       Impact factor: 6.514

Review 4.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 5.  Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.

Authors:  Ralph A Defronzo
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

6.  Antagonistic modulation of NPY/AgRP and POMC neurons in the arcuate nucleus by noradrenalin.

Authors:  Lars Paeger; Ismene Karakasilioti; Janine Altmüller; Peter Frommolt; Jens Brüning; Peter Kloppenburg
Journal:  Elife       Date:  2017-06-20       Impact factor: 8.140

7.  Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.

Authors:  Motoyuki Igata; Yoshitaka Yagi; Satoko Hanatani; Masaji Sakaguchi; Norio Ishii; Kayo Yoshinaga; Junji Kawashima; Hiroyuki Motoshima; Eiichi Araki
Journal:  J Diabetes Investig       Date:  2020-08-25       Impact factor: 4.232

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.